Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Holds Hospital Outpatient Payment For Drugs At ASP+4% For 2010

This article was originally published in The Pink Sheet Daily

Executive Summary

Draft rule for Part B hospital outpatient prospective payment system in 2010 goes against advisory panel recommendation to increase reimbursement to average sales price plus 6 percent. Other changes affecting drugs and biologicals are proposed.
Advertisement

Related Content

CMS Methodology, Not Industry Complaints, Brings Proposed Hospital Part B Outpatient Drug Reimbursement Back To ASP+6% in 2011
CMS Methodology, Not Industry Complaints, Brings Proposed Hospital Part B Outpatient Drug Reimbursement Back To ASP+6% in 2011
Zevalin Completes Transition To ASP-Based Reimbursement In OPPS
Zevalin Completes Transition To ASP-Based Reimbursement In OPPS
BIO Critiques CMS' Justification Of ASP+4% For Hospital Outpatient Drugs
BIO Critiques CMS' Justification Of ASP+4% For Hospital Outpatient Drugs

Topics

Advertisement
UsernamePublicRestriction

Register

PS069788

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel